Wells Fargo & Company Cytek Biosciences, Inc. Transaction History
Wells Fargo & Company
- $433 Billion
- Q4 2024
A detailed history of Wells Fargo & Company transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 71,240 shares of CTKB stock, worth $299,208. This represents 0.0% of its overall portfolio holdings.
Number of Shares
71,240
Previous 55,724
27.84%
Holding current value
$299,208
Previous $308,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CTKB
# of Institutions
151Shares Held
74MCall Options Held
1KPut Options Held
0-
Black Rock Inc. New York, NY17.1MShares$71.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$49.2 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD8.25MShares$34.6 Million1.27% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$28 Million1.65% of portfolio
-
State Street Corp Boston, MA4.51MShares$18.9 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $565M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...